Major depression (MDD) is a significant cause of morbidity & mortality in children & adolescents. Numerous antidepressant agents have been demonstrated to have safety & efficacy in the adult population. However, there is little information on the safety & efficacy of these agents in children & adolescents. To date, only one anti-depressant, fluoxetine, has demonstrated safety & efficacy for the treatment of MDD in children & adolescents. Venlafaxine, a non-specific serotonin re-uptate inhibitor, is an anti-depressant that has received FDA approval for treating depression in the adult poopulation. A formulation of extended-release venlafaxine, venlafaxine ER(V-ER), has now been developed in order to provide once-daily dosing in contrast to the BID or TID dosing of regular, or """"""""immediate release"""""""" venlafaxine (V-IR). Preliminary studies for V-ER in adult patients suggest similar efficacy & possibly better tolerability than V-IR. V-ER is of merit in treating depression because of its mixed catecholiminergic & serotonergic activity, its relatively simple side-effect profile at recommended doses, as well as once-a-day dosing. This profile suggests V-ER is of interest in treating the pediatric population because it could have robust antidepressant qualities in addition to helping improve compliance of venlafaxine treatment.

Project Start
2000-12-01
Project End
2001-11-30
Budget Start
Budget End
Support Year
40
Fiscal Year
2001
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Altekruse, Sean F; Shiels, Meredith S; Modur, Sharada P et al. (2018) Cancer burden attributable to cigarette smoking among HIV-infected people in North America. AIDS 32:513-521
Salemi, Parissa; Skalamera Olson, Julie M; Dickson, Lauren E et al. (2018) Ossifications in Albright Hereditary Osteodystrophy: Role of Genotype, Inheritance, Sex, Age, Hormonal Status, and BMI. J Clin Endocrinol Metab 103:158-168
Robert Braši?, James; Mari, Zoltan; Lerner, Alicja et al. (2018) Remission of Gilles de la Tourette Syndrome after Heat-Induced Dehydration. Int J Phys Med Rehabil 6:
Altman, Matthew C; Whalen, Elizabeth; Togias, Alkis et al. (2018) Allergen-induced activation of natural killer cells represents an early-life immune response in the development of allergic asthma. J Allergy Clin Immunol 142:1856-1866
AIDS-defining Cancer Project Working Group of IeDEA, COHERE in EuroCoord (2018) Non-Hodgkin lymphoma risk in adults living with HIV across five continents. AIDS 32:2777-2786
Juraschek, Stephen P; Miller 3rd, Edgar R; Appel, Lawrence J (2018) Orthostatic Hypotension and Symptoms in the AASK Trial. Am J Hypertens 31:665-671
Elion, Richard A; Althoff, Keri N; Zhang, Jinbing et al. (2018) Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV. J Acquir Immune Defic Syndr 78:62-72
Al-Sofiani, Mohammed E; Yanek, Lisa R; Faraday, Nauder et al. (2018) Diabetes and Platelet Response to Low-Dose Aspirin. J Clin Endocrinol Metab 103:4599-4608
Grover, Surbhi; Desir, Fidel; Jing, Yuezhou et al. (2018) Reduced Cancer Survival Among Adults With HIV and AIDS-Defining Illnesses Despite No Difference in Cancer Stage at Diagnosis. J Acquir Immune Defic Syndr 79:421-429
Grams, Morgan E; Sang, Yingying; Ballew, Shoshana H et al. (2018) Predicting timing of clinical outcomes in patients with chronic kidney disease and severely decreased glomerular filtration rate. Kidney Int 93:1442-1451

Showing the most recent 10 out of 1014 publications